CD36 and type 2 diabetes mellitus: The present study is the first to demonstrate that a DPP-4 inhibitor has the potential to suppress foam cell formation via CD36 and ACAT-1 in macrophages isolated from diabetic db/db mice and T2D patients ex vivo.